Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Barth, DA; Stanzer, S; Spiegelberg, JA; Bauernhofer, T; Absenger, G; Szkandera, J; Gerger, A; Smolle, MA; Hutterer, GC; Ahyai, SA; Madl, T; Posch, F; Riedl, JM; Klec, C; Jost, PJ; Kargl, J; Stradner, MH; Pichler, M.
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Front Immunol. 2022; 13: 840207 Doi: 10.3389/fimmu.2022.840207 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz

Barth Dominik Andreas

Pichler Martin

Stradner Martin Helmut

Co-Autor*innen der Med Uni Graz

Absenger Gudrun

Ahyai Sascha

Bauernhofer Thomas

Gerger Armin

Hutterer Georg

Jost Philipp

Kargl Julia

Klec Christiane

Madl Tobias

Posch Florian

Riedl Jakob

Smolle Maria Anna

Spiegelberg Jasmin Alija

Stanzer Stefanie

Szkandera Joanna

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Background: Immune checkpoint inhibitors (ICIs) have revolutionized systemic anti-tumor treatments across different types of cancer. Nevertheless, predictive biomarkers regarding treatment response are not routinely established yet. Apart from T-lymphocytes, the humoral immunity of B-lymphocytes is studied to a substantially lesser extent in the respective setting. Thus, the aim of this study was to evaluate peripheral blood B-cell subtypes as potential predictors of ICI treatment response. Methods: Thirty-nine cancer patients receiving ICI therapy were included into this prospective single-center cohort study. All had a first blood draw at the date before treatment initiation and a second at the time of first response evaluation (after 8-12 weeks). Seven different B-cell subtypes were quantified by fluorescence-activated cell sorting (FACS). Disease control- (DCR) and objective response rate (ORR) were co-primary study endpoints. Results: Overall, DCR was 48.7% and ORR was 25.6%, respectively. At baseline, there was no significant association of any B-cell subtype with neither DCR nor ORR. At the first response evaluation, an increase in the frequency of CD21^- B-cells was a statistically significant negative predictor of response, both regarding DCR (OR=0.05, 95%CI=0.00-0.67, p=0.024) and ORR (OR=0.09, 95%CI=0.01-0.96, p=0.046). An increase of the frequency of switched memory B-cells was significantly associated with reduced odds for DCR (OR=0.06, 95%CI=0.01-0.70, p=0.025). Patients with an increased frequency of naïve B-cells were more likely to benefit from ICI therapy as indicated by an improved DCR (OR=12.31, 95%CI=1.13-134.22, p=0.039). Conclusion: In this study, certain B-cell subpopulations were associated with ICI treatment response in various human cancer types.

Find related publications in this database (using NLM MeSH Indexing)

B-Lymphocytes - administration & dosage

Cohort Studies - administration & dosage

Humans - administration & dosage

Immune Checkpoint Inhibitors - therapeutic use

Neoplasms - drug therapy

Progression-Free Survival - administration & dosage

Prospective Studies - administration & dosage

Find related publications in this database (Keywords)

B cells

cancer

immune checkpoint inhibitor therapy

lymphocytes

response

© Med Uni Graz • Impressum